Moderna, a biotech firm, has received a $590 million award from the US government to accelerate development of an mRNA-based vaccine against bird flu. The company’s Phase 1/2 study on mRNA-1018 candidate showed positive results in healthy adults aged 18 and up. Moderna plans to move to a Phase 3 trial. As bird flu continues to spread globally, with outbreaks in poultry and US dairy cows, the CDC warns of low public health risk but is closely monitoring the situation. This news comes as egg prices rise due to production limits caused by the outbreak.
Source: https://www.investopedia.com/moderna-stock-jumps-as-biotech-gets-usd590m-from-us-to-develop-bird-flu-vaccine-8777657